SDGR Stock Recent News

Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.71. This compares to loss of $0.76 per share a year ago.

Schrödinger, Inc. (NASDAQ:SDGR ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Jaren Madden - Senior Vice President, Investor Relations & Corporate Affairs Ramy Farid - President & Chief Executive Officer Geoff Porges - Chief Financial Officer Karen Akinsanya - President, R&D & Therapeutics Conference Call Participants Michael Yee - Jefferies Brendan Smith - TD Cowen Mani Foroohar - Leerink Partners Evan Seigerman - BMO Capital Markets Michael Ryskin - Bank of America Scott Schoenhaus - KeyBanc Vikram Purohit - Morgan Stanley Operator Thank you for standing by. Welcome to Schrödinger's conference call to review First Quarter 2025 Financial Results.

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. today announced financial results for the quarter ended March 31, 2025.

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the BofA Securities 2025 Healthcare Conference. The live presentation will take place on Wednesday, May 14, 2025 at 4:40 p.m. ET. The live webcast can be accessed in the “Investors” section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computatio.

CHICAGO--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) presented preclinical data on SGR-3515, its investigational Wee1/Myt1 co-inhibitor today at the American Association for Cancer Research (AACR) Annual Meeting 2025. The data demonstrated that SGR-3515 has improved anti-tumor activity in preclinical models compared to known Wee1 and Myt1 monotherapy inhibitors. The poster also described how the dosing schedule of SGR-3515 can be optimized to preserve efficacy and minimize target-related.

NEW YORK--(BUSINESS WIRE)--Schrödinger will report its first quarter 2025 financial results on Wednesday, May 7, 2025, after the financial markets close.

While the impact of unanticipated tariff policy changes in early April was market-wide, the recovery has been less even. Despite a major rebound following the sell-off, some firms have been sluggish to reclaim lost ground.

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on April 16, 2025, the company granted (i) a non-statutory stock option to purchase 3,300 shares of the company's common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 12,866 shares of the company's common stock to six newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of.

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) strongly supports the U.S. Food and Drug Administration's (FDA) plan to reduce, refine or potentially replace current animal testing requirements with new approaches designed to improve drug safety and accelerate the evaluation process, while reducing animal experimentation. The FDA's roadmap encourages a number of computational approaches to predict drug properties. Schrödinger's widely used computational platform enables highly accur.

Schrodinger (SDGR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.